Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, will offer Propofol as the first product within its KinetiX platform of RTA syringe products at the Annual National Pharmacy Purchasing Association Conference (Booth #603-605).
“Following the recent 503B registration and licensing of our facility in North Carolina, Genixus is excited to deliver an RTA format of Propofol, one of the most commonly used medications within the OR setting” said Seth Coombs, co-founder and chief commercial officer of Genixus. “Our KinetiX platform is designed to deliver clinical tools that seamlessly integrate into the operations of the acute and critical care setting, allowing clinicians to focus on their ultimate goal: the quality of care and patient outcomes.”
The new Propofol Syringe is the first product to be available within the KinetiX RTA platform, which is designed to simplify workflow and support effective care delivery. To support error resistance and clinical efficiency, KinetiX Propofol features several key attributes:
- Long-term shelf stability
- ISMP-driven label
- Color-coded plunger rod
- Auto-dispensing cabinet (ADC) ready
- RFID-enabled
- 10mL and 20mL formats
“The new KinetiX RTA platform will support error resistance for our patients by addressing the risk of vial and syringe swap medication errors as well as the risk of contamination when drawing medication out of a vial,” said Jason Erlich, MD, anesthesiologist in Boston, Massachusetts, and advisor to Genixus.
